4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Gossamer Bio, Inc. (GOSS) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 161 employees. Its market capitalization is roughly $85 million. In the fiscal year ended 2025-12-31, GOSS reported $48M in revenue and ($170M) in net income.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
Interactive charts & full statements → Open the GOSS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $48M | $115M | $0M | $0M | — |
| Operating Income (EBIT) | ($163M) | ($60M) | ($174M) | ($218M) | — |
| Net Income | ($170M) | ($56M) | ($180M) | ($229M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $17M | $14M | $13M | $12M | $10M | — |
| Operating Income (EBIT) | ($45M) | ($46M) | ($42M) | ($39M) | ($37M) | — |
| Net Income | ($47M) | ($47M) | ($48M) | ($38M) | ($37M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $172M | $315M | $312M | $272M | — |
| Total Liabilities | $295M | $286M | $249M | $260M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GOSS viewer.
About TickerBase · Data methodology & sources